{"filing":{"accession_number":"0001829126-26-009454","cik":"0001479419","ticker":"KALA","company_name":"KALA BIO, Inc.","form":"8-K","filing_date":"2026-08-28","report_date":"2026-08-27","primary_document":"kalabio_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479419/000182912626009454/kalabio_8k.htm"},"events":[{"id":30168,"run_id":27650,"accession_number":"0001829126-26-009454","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"KALA BIO received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a reverse stock split effected on May 11, 2026, and faces potential delisting unless it successfully appeals to the Nasdaq Hearings Panel. This is a classic delisting-risk disclosure under Item 3.01.","company_name":"KALA BIO, Inc.","ticker":"KALA","filing_date":"2026-08-28","form":"8-K","submitted_at":null,"items":[{"id":32693,"accession_number":"0001829126-26-009454","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"KALA BIO received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a reverse stock split effected on May 11, 2026, and faces potential delisting unless it successfully appeals to the Nasdaq Hearings Panel. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:46:45.834588+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32693,"accession_number":"0001829126-26-009454","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"KALA BIO received a Staff Determination Letter from Nasdaq on August 27, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a reverse stock split effected on May 11, 2026, and faces potential delisting unless it successfully appeals to the Nasdaq Hearings Panel. This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-28T10:46:45.834588+00:00","company_name":"KALA BIO, Inc.","ticker":"KALA","filing_date":"2026-08-28"}]}